Brain Tumour Survival Rates

Clive Jones Excerpts

Monday 9th February 2026 Commons Chamber

[Clive Jones (Wokingham) (LD)]

I thank the hon. Member for Mitcham and Morden (Dame Siobhain McDonagh) and my hon. Friend the Member for Witney (Charlie Maynard) for securing this evening’s important debate. Brain cancer is a particularly nasty and lethal form of cancer, and one of the least improved cancers in terms of survival rates. Brain tumours are the biggest cancer killer of adults and children under 40 and are largely unpreventable. After years of Conservative neglect of cancer care, the Government’s recent national cancer plan takes steps to address the crisis in cancer care. That is definitely to be welcomed, but it is clear that brain cancer care still needs urgent attention.

A big cause of low brain cancer survival rates is slow diagnosis. In England, 45% of patients are diagnosed in an emergency setting—over two times the rate of all other cancers. Emergency diagnosis means that patients often face worse chances of survival and fewer treatment options, especially options that avoid harm. The Government must act to ensure that brain cancer is caught earlier to give patients a better chance of survival. That is why the Government must speed up the diagnostic pathway by improving GP access to diagnostic imaging and improve the patchy access to MRI and CT scans.

Even when a patient gets a diagnosis, many experience delays in starting treatment. In 2024, 75% of brain cancer patients at the Royal Berkshire hospital near my constituency began treatment within 62 days of an urgent referral. That is below the standard expected proportion of 85%. Even more shocking is that, in 2023, 25% of brain cancer patients at the Royal Berks waited longer than 124 days to begin treatment after an urgent referral. That is just not good enough, which is why my colleagues, and many others in the House, are calling on the Government to introduce a guarantee for 100% of patients to start treatment for cancer within 62 days of an urgent referral. The Government must start to listen to the people who are calling for that.

A key step towards this aim is improving access to effective treatment. In the Buckinghamshire, Oxfordshire and Berkshire West integrated care board, which covers Wokingham, just 30% of cancer patients receive radiotherapy treatment within the 62-day treatment standard. This means that many brain cancer patients in Wokingham are missing out on the effective and timely treatment that would drastically improve their survival outcomes. To help address this, the Government need to replace ageing radiotherapy machines as soon as possible and invest in new ones, so that no one is denied access to treatment or has to travel far from home.

There is also a serious issue with equal access to new advanced treatments for brain cancer. Personalised immunotherapy vaccines have proven to be an effective treatment for brain cancer. This treatment, as well as advanced diagnostics and research, requires brain tissue from a patient to be flash-frozen to preserve DNA and RNA. It is then used to develop rounds of an immunotherapy vaccine. Due to a lack of nationwide regulations and practices on brain tissue freezing, however, there is a shameful inequality in brain cancer care. Sadly, the Royal Berkshire hospital and Frimley hospital, both used by my constituents, do not have the capability to flash-freeze or store brain tissue. As a result, many in Wokingham and across Berkshire cannot access advanced technologies such as personalised immunotherapy treatment and the more accurate genome sequencing that are key to attacking the cancer effectively.

This is why the Government must ensure equal access to high-quality tissue storage pathways across the country. It is not right that where someone lives affects the treatment they get, and thus their chances of survival. These steps to speed up diagnosis and improve treatment, along with investment in staff and research, will start to improve survival rates for the 12,700 people diagnosed with a brain tumour every year in the UK. Lastly, much has been mentioned about clinical trials in this debate. They are needed desperately, and it is my hope that Ministers will make this their personal priority in their discussions with drug companies in the next few months, and that we will see some real progress, with many more clinical trials starting in the next few years.